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IFN-λ is the newly established type III IFN with unique immunomodulatory functions. In 
contrast to the IFN-α/β family and to some extent IFN-γ, IFN-λ is apparently acting in 
specific areas of the body to activate resident immune cells and induces a local immunity, 
instrumental in preventing particular infections and also keeping transformed cells under 
control. Mucosal areas of lung and gastrointestinal tracts are now under scrutiny to 
elucidate the immune mechanisms triggered by IFN-λ and leading to viral protection. 
New evidence also indicates the crucial role of IFN-λ in promoting innate immunity in 
solid cancer models. Based on its unique biological activities among the IFN system, new 
immunotherapeutic approaches are now emerging for the treatment of cancer, infection, 
and autoimmune diseases. In the present review, we highlight the recent advances of 
IFN-λ immunomodulatory functions. We also discuss the perspectives of IFN-λ as a 
therapeutic agent.
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iNTRODUCTiON
Human IFN-λs are represented by four functional and highly homologous subtypes IFN-λ1, 
IFN-λ2, IFN-λ3, and IFN-λ4 (1, 2). In contrast to the other IFN-λ subtypes, IFN-λ4 is selectively 
expressed in the human population and weakly released by IFN-producing cells (3). However, 
all the four IFN-λ protein subtypes are clustered on chromosome 19 and are grouped in a new 
IFN family, called type III IFN, distinct from type I and type II IFNs, respectively, representing 
the classical IFN-α/β family and IFN-γ. In mice, only two functional genes located on chromo-
some 7 and encoding IFN-λ2 and IFN-λ3 have been characterized (4). In contrast to its human 
counterpart, the murine IFN-λ1 gene ortholog is a pseudogene as reported in several mice strains. 
However, we did not find yet a corresponding IFN-λ4 in mice. Type III IFNs use a unique recep-
tor, the IFN-λ receptor, and induces similar JAK–STAT signaling pathway as type I IFNs (5, 6). 
Although it has been well established that in addition to JAK1, TYK2 is crucial in mediating the 
activity of both type I and type III IFN, new evidence in patients with a defect in TYK2 shows 
an impaired response for type I IFN only (7), suggesting a Tyk2-independent signaling for type 
III IFN. Upstream cell signaling is quite distinct between type I and type III IFN. Type I IFN 
interacts with a receptor formed by IFNAR1 and IFNAR2 (8). However, type III IFNs bind to 
the specific receptor chain IFN-λR1, and IL-10R2, a receptor subunit shared by IL-10 cytokine 
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family members IL-10, IL-22, and IL-26 (6). In contrast to type 
I and type II IFN receptors, the unique type III IFN receptor for 
IFN-λ, IFN-λR1 is not ubiquitously expressed (5, 9), suggesting 
that IFN-λ may eradicate specific viral infections and also elicit 
a more local immunity against pathogens and cancers. This has 
important consequences for therapeutic targeting (10, 11).
In addition to its restricted interaction mainly with epithelial 
cells (EC), IFN-λ may also induce cell signaling that differs to 
some extend from IFN-α/β signaling. Currently, it has been 
established that the antiviral patterns of IFN-λ are quite distinct 
from those of IFN-α (10). In oncology and autoimmune dis-
eases, the role of IFN-λ seems also to differ in many aspects from 
IFN-α (11).
Furthermore, in contrast with type I, type III IFN is prone to 
a particular genetic reactivation or deactivation in the human 
population as illustrated with IFN-λ4 and related genetic poly-
morphism (3). Tremendous research efforts are still ongoing to 
understand the impact of this genetic aspect of type III IFN on 
the prevalence of diseases, particularly hepatitis. IFN-λ4 has 
been linked with the failure to clear hepatitis C virus (HCV) 
infection and decreased response of HCV patients to IFN-α 
therapy (12, 13). IFN-λ4 can be produced only by people who 
carry the IFN-λ4–ΔG allele (rs368234815), known for predict-
ing HCV clearance (3, 14). The inherited IFN-λ4–ΔG allele is 
the main variant in Africans, while the minor variant is found 
in Asian people (15). Therefore, a negative genetic selection for 
IFN-λ4–ΔG allele could be driven by infectious agents, includ-
ing HCV (16).
As highlighted in many reviews, the activity of IFN-λ is highly 
prominent in EC in comparison with other cell types (1, 3, 5, 
9–11, 17–24). However, the significance of the restricted action 
of IFN-λ remains elusive. We still have to understand the role of 
this specific interaction of IFN-λ on the protection of epithelial 
surfaces from exposure to pathogenic microbes and the develop-
ment of carcinomas. The goal of this review is not an exhaustive 
description of the IFN-λ biology, which has been abundantly 
reported in many important reviews (5, 10, 20, 22–25). We have 
been focusing our review on the potential links between the 
prominent activity of IFN-λ on EC and its associated immunity 
against viral infections and cancer.
iFN-λ AND THe ePiTHeLiUM TRACT 
DeFeNSe AGAiNST viRAL iNFeCTiONS
Accumulating evidence strongly suggests that IFN-λ plays a major 
role in providing the frontline defense for the epithelium against 
viruses. The epithelium is formed by closely packed EC with 
practically no intercellular spaces. However, EC are not isolated 
from immune cells. Respiratory, urogenital, and gastrointestinal 
(GI) tracts forming the major mucosal areas in the body show 
complex association between the epithelium and the immune 
cells in variable proportions, endowing mucosal surfaces with 
a particular immunity against the harmful environment (26). 
By lining mucosal surfaces, EC are under continuous attack by 
viruses. The first response of cells infected with virus is the release 
of IFN. The released IFN provides neighboring healthy cells an 
antiviral state, allowing them to stop viral spreading (Figure 1). 
However, clearance of infected cells requires immune cells inter-
vention. Both type I and type III IFNs are expressed by host cells 
in response to viral infection. However, depending on the site of 
virus attack, host cells exhibit differential expression of type I and 
type III IFNs (5, 25, 27). The mechanisms leading to the induction 
of IFN expression, the establishment of antiviral state, and the 
clearance of infected cells are well documented particularly for 
type I IFN (10). In contrast, we are still striving to understand the 
role of IFN-λ-regulated antiviral mechanisms in mucosal surfaces 
on which increasing reports indicate a critical role of type III IFN.
ROLe OF iFN-λ iN THe CONTROL OF 
viRAL iNFeCTiONS OF THe 
ReSPiRATORY TRACT
Respiratory tract infections by viruses are common and mainly 
concern the sinus, the throat, and the lungs. In comparison 
with IFN-α, IFN-λ is predominantly induced by respiratory 
viruses (28–31). Currently, IFN-λ is designated as a therapeutic 
candidate against the influenza A virus (IAV) infection (32, 33). 
In infants hospitalized for respiratory syncytial virus (RSV)- or 
human rhinovirus (HRV)-associated bronchiolitis, RSV elicited 
higher levels of IFN-λ subtypes when compared with HRV (34).
It has been postulated that in order to increase infection, 
respiratory viruses can also suppress IFN-λ antiviral response. 
Influenza virus- and RV-induced epidermal growth factor recep-
tor activation has been found to suppress IFN regulatory factor 
(IRF)-1-induced IFN-λ production and increased viral infection 
(35). NS1 and NS2 proteins of the human RSV also inhibit IFN-λ 
production, occurring via IFN regulatory factor (IRF)-3, NF-κB, 
and proinflammatory cytokines suppression (36, 37). More 
recently, it has been reported that excessive expression of IFN-λ 
in the lung during IAV infection is associated with a suppression 
of IFN-λ signaling by SOCS-1 (31). The authors suggested that 
the suppression of cytokine signaling by virus-induced SOCS-1 
leads to an adaptive increase in IFN-λ production by the host 
to protect cells against viral infection. This increase of IFN-λ 
production further induces the expression of SOCS-1 at late stage 
of infection, which in turn, inhibits the activation of JAK–STAT 
signaling. Finally, this vicious cycle results in excessive produc-
tion of IFN-λ and impaired antiviral activity.
One of the main concerns about viral lung infections such as 
the one caused by IAV is the subsequent inflammation. Although 
IFN-α is highly efficient in suppressing IAV, in contrast with 
IFN-λ, it exacerbates the inflammation by overstimulating the 
immune system and driving immunopathology (32). Therefore, 
in agreement with its weak targeted actions on immune cells 
surrounding infected EC, IFN-λ may constitute the treatment 
of choice in viral infections associated with inflammation 
(11). In favor of IFN-λ as therapeutic option for viral infection 
associated with inflammation, we can mention early studies on 
asthma, showing a deficiency in IFN-λ (38) and the role of IFN-λ 
treatment in suppressing respiratory viral infections and allergic 
airway inflammation (39). However, other immune mechanisms 
could also occur after IFN-λ treatment. It has been strongly 
FiGURe 1 | Production of iFN-λ and establishment of the antiviral state. After virus attack, IFN-λ genes are induced. When viral particle ligands (VPL) are 
sensed by pattern recognition receptors (PRRs), particular transcription factors, mainly IRF-3 and NF-κB, are induced to allow IFN-λ gene expression and 
subsequent release of IFN-λ proteins outside the infected cell. Dependent on the type of virus, various PRRs are involved, including members of the RIG-I-like 
receptor and toll-like receptor families, as well as the DNA sensor Ku70. Released IFN-λ induces an antiviral state in neighboring cells via the induction of 
interferon-stimulated gene factor leading to the expression of specific antiviral interferon-stimulated genes (ISGs), including myxovirus resistance 1, protein kinase 
R, melanoma differentiation-associated protein 5, verpin, and 2′-5′-oligoadenylate synthetase. Products of those antiviral ISGs inhibit virus replication and provide 
an antiviral state to cells.
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suggested that by upregulating indoleamine 2,3-dioxygenase 
during influenza virus infection, IFN-λ may induce an immune 
suppression (40).
ROLe OF iFN-λ iN THe CONTROL 
OF viRAL iNFeCTiONS OF THe 
GASTROiNTeSTiNAL TRACT
Currently, several studies indicate that IFN-λ plays a predomi-
nant role in controlling viral infections of the GI tract (5, 10, 41, 
42). In response to viral infections, IFN-λ is highly produced 
by intestinal EC and induces a strong antiviral response (27). 
However, recent studies show that this strong effect of IFN-λ 
resulted from a synergistic effect with IL-22 (43). ZEB1 has been 
shown to play a role in the activation of IFN-λ gene expression 
at the transcriptional level, in addition to IRF-3 and NF-κB (10, 
44). Interestingly, the role of IFN-λ in controlling viral infections 
of the GI tract cannot be compensated by IFN-α/β in suckling 
mice (25).
In contrast to type I IFN, type III IFN was not involved in 
controlling viral infection of lamina propria in agreement with 
the lack of response of effector immune cells to IFN-λ but not 
to IFN-α (Figure 2). Therefore, type I and type III IFNs are not 
redundant cytokines at least in the GI tract (25, 45).
Regarding the role of IFN-λ during rotavirus infection, diver-
gent results between virus strains and research groups have been 
reported. Early studies showed that IFN-λ is highly effective in 
controlling the murine rotavirus infection in suckling mice (27, 
43). However, Lin et al. demonstrated that the effect of IFN-λ is 
dependent on the rotavirus strain used (46, 47). IFN-λ was able 
to control rotavirus infection when suckling mice received the 
heterologous but not the homologous rotavirus. Although the 
homologous rotaviruses used by those different groups are quite 
similar, the IFN-λR1 knock-out mice used in the more recent 
study were generated differently. In this study, only exon 3 of 
IFN-λR1 gene is lacking, while in the transgenic mice used by 
the other groups, the entire IFN-λR1 gene is missing. Although 
the first generated IFN-λR1-deficient mice have been exten-
sively studied by many groups for almost a decade (48), com-
parison between the two IFN-λR1-deficient mice is warranted. 
Important standardizations of virus dosage, virus strain, host 
strain, and diet are also required for minimizing the variance in 
the experimentation.
FiGURe 2 | Concerted action of iFN-λ and iFN-α promotes mucosal immunity and viral protection. After the interaction of the epithelium surface of the 
mucosa with viruses, epithelial cells release IFN-λ. The process leading to IFN-λ production is triggered by the interaction of a viral particle ligand (VPL) such as DNA 
or RNA with the cellular pattern recognition receptors. Dendritic cells (DCs) are the main immune cells of the mucosa involved in sensing viral infections and 
producing high amounts of IFN-λ and IFN-α. This produced IFN-λ fuels the antiviral protection of the epithelium and in concert with IFN-α may shape local immunity 
and control inflammation. Released IFN-α by DCs also plays a central role in controlling viral dissemination in the lamina propria and the promotion of T cell immunity 
and natural killer cell activation for immediate targeting and clearance of infected cells toward stopping viral spread.
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ROLe OF iFN-λ iN THe CONTROL OF 
vAGiNAL MUCOSA iMMUNiTY
Herpes simplex virus particularly 2 (HSV-2) is the prevalent 
cause of genital ulceration in humans worldwide with lifelong 
latent infection of female genital mucosa (49). Early studies in 
mice using a model of localized HSV-2 infection demonstrate that 
IFN-λ completely prevents virus replication in the vagina. IFN-λ 
has been shown to induce significant virus suppression associated 
with a complete remission from the genital viral disease. Antiviral 
effects of IFN-λ were superior in comparison with IFN-α (48, 
50, 51). In a recent study using BAC transgenic mice, expressing 
firefly luciferase under transcriptional control of the Mx2 gene 
promoter, it has been also demonstrated that IFN-λ reactivity 
was most prominent in mucosal surfaces, including the genital 
area; however, IFN-α response was strong in the liver, spleen, 
and kidney (52). Furthermore, the vaginal mucosa expresses high 
levels of IFN-λ. In contrast to IFN-α, NF-κB plays a major role in 
promoting IFN-λ expression (53). The primary source of IFN-λ 
was attributed to dendritic cells (DCs), indicating that IFN-λ 
response plays a crucial role in promoting vaginal mucosa immu-
nity (Figure 2). Ongoing investigations, using IFN-λ transgenic 
models, will likely determine the effector cells responsible for the 
control of vaginal infection by IFN-λ.
PeRSPeCTiveS AND CHALLeNGeS OF 
iFN-λ AS A New PLAYeR iN MUCOSAL 
SURFACeS
The role of IFN-λ in controlling viral infection of mucosal surfaces 
is increasingly studied (5, 10). The interaction between IFN-λ and 
the EC of the mucosa is a crucial step in establishing this anti-
viral protection. In comparison with IFN-α, the antiviral effect 
of IFN-λ on the lining epithelium appears significantly superior. 
However, IFN-λ fails to control viral infection of immune areas 
underlying the epithelium. Conversely, IFN-α appears more 
efficacious than IFN-λ in protecting immune tissues and lamina 
propria from viral infection. By playing complementary roles, 
both IFN-λ and IFN-α seem instrumental in protecting mucosal 
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surfaces from viruses. However, the role of immune cells that 
contributes to the antiviral activity of IFN-λ and IFN-α remains 
poorly understood. Besides DCs, we still poorly understand the 
contribution of other immune system components in IFN-λ 
functions within the mucosa. It has been clearly demonstrated 
that the mean source of IFN-λ in the mucosa is coming from 
the DCs. This released IFN may fuel the antiviral protection of 
EC, and probably in concertation with IFN-α, modulates mucosal 
immunity and inflammation (Figure  2). However, studies in 
this field concern mostly IFN-α. The role of IFN-α in activating 
immune cells during viral infection of the mucosa and related 
inflammation has been relatively well studied (10). The question 
yet to be answered is, in the context of IFN-α and viral infections, 
what is the role of IFN-λ in innate immunity and inflammation, 
particularly in neonates and infants?
Due to their innate immune deficiency, neonates and infants 
are highly sensitive to respiratory and GI virus infections leading 
to high risk of mortality (54, 55). Immaturity of natural killer 
(NK) cells has been demonstrated as the primary factor for 
increased susceptibility to viral infections in early life for both 
human and mice (56–59). NK cell responses’ impairments are 
associated with a significant deficiency in the production and 
the release of lytic granules (60), in agreement with early studies 
demonstrating that the transfer of adult NK cells to suckling mice 
induces a protection against viral infection (61). This conclusion 
has been corroborated by a recent report demonstrating that NK 
cell deficit can be reversed in suckling mice (62). In parallel, as 
reported earlier, it has been shown that IFN-λ plays a crucial role 
in viral infections of suckling mice (27, 43, 46, 47), suggesting 
that IFN-λ may induce antiviral functions at least partially via 
NK cells, and those functions of IFN-λ are missing in neonates 
and infants due to a potential deficiency of IFN-λ production or 
response. The aptitude of NK cells to respond rapidly without 
prior sensitization makes them at the front line of defense against 
infection (63, 64). NK cells are well armed for sensing and kill-
ing virus-infected cells (Figure 2). In vivo activation of NK cells 
by IFN-λ has been well documented in cancer models (6, 65). 
Significant NK cell impairment of NK cell tumoricidal activity 
has been reported in IFN-λR−/− mice (66). More recently, we 
have demonstrated that a cooperation between IFN-λ and IFN-α 
promoted local NK cell antitumor actions (67). We believe that 
within mucosal surfaces, IFN-λ in combination with IFN-α may 
play an important role in recruiting and activating NK cells to 
clear viral infections. Privileged interaction of IFN-λ with EC 
may not only induce the antiviral state but also contribute to the 
attraction of immune cells via the release of potential chemokines.
In addition to its role in mucosal immunity and viral infec-
tions, IFN-λ has been recently proposed as the treatment of 
choice for IAV infection because its antiviral activity was not 
associated with an exacerbation of inflammation in contrast to 
IFN-α (32). However, the mechanisms leading to the potential 
anti-inflammatory role of IFN-λ remain elusive. In the case of 
IAV infection, it has been indicated that IFN-λ was simply acting 
on EC without overstimulating the immune system and driving 
immunopathology like IFN-α. However in collagen-induced 
arthritis, the anti-inflammatory role of IFN-λ has been demon-
strated (68). Apparently, IFN-λ decreased significantly neutrophil 
population in the joints of diseased mice. This occurred in asso-
ciation with a reduction of interleukin-1β level, which is thought 
to play a crucial role in inflammation.
CONCLUSiON
We currently see a clearer picture about the role of IFN-λ and its 
possible therapeutic uses. All studies highlight the crucial role of 
IFN-λ on EC, which are the first line of attack by pathogens, tox-
ins, and other damaging agents. The majority of infections and 
cancers concern epithelial cell types. This strongly suggests that 
beyond its well-described antiviral and antitumoral roles, IFN-λ 
may have immunomodulatory roles for indirectly protecting EC 
from different damages. New ideas have already emerged about 
the role of IFN-λ on effector cells orchestrating inflammation 
and autoimmunity. However, for building successful strategies 
against cancer and infection diseases, the interaction between 
IFN-λ and IFN-α should be taken into consideration. Based 
on new evidence from viral infections and cancer studies a 
concerted action of IFN-α and IFN-λ seems crucial in the com-
plexity of interactions between diseased cells and surrounding 
immune cells.
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